Mar 21, 2023 / 04:00PM GMT
Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division - MD & Senior Analyst
This is Paul Knight, the analyst covering Life Science Catalent at KeyBanc. I'd like to welcome Tom Castellano, Chief Financial Officer of Catalent. Paul Surdez is also attending as well. I'd like to thank them for their time. Tom, I guess if you'd like, you could make a couple of pennies, but or I could just start with some Q&A as well, whatever you would prefer.
Thomas P. Castellano - Catalent, Inc. - Senior VP & CFO
Yes. No, Paul, I think we can start with Q&A, we've been on the conference circuit here for a couple of weeks now. So I would say no new information for me to reiterate here. So happy to dive right into your Q&A.
Questions and Answers:
Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division - MD & Senior AnalystOkay. And starting with COVID expectations for calendar 2023, how it rolls out kind of your thoughts on size, timing, et cetera?
Thomas P.
Trustpilot
